医学
贝伐单抗
转移性乳腺癌
维持疗法
内科学
肿瘤科
乳腺癌
临床终点
富维斯特朗
化疗
癌症
外科
临床试验
三苯氧胺
作者
Shigehira Saji,Naruto Taira,Masahiro Kitada,Toshimi Takano,Masahiro Takada,Tohru Ohtake,Tatsuya Toyama,Yuichiro Kikawa,Yoshie Hasegawa,Tomomi Fujisawa,Masahiro Kashiwaba,Takanori Ishida,Rikiya Nakamura,Yutaka Yamamoto,Uhi Toh,Hiroji Iwata,Norikazu Masuda,Satoshi Morita,Shinji Ohno,Masakazu Toi
标识
DOI:10.1016/s1470-2045(22)00196-6
摘要
Anticancer treatment regimens typically cause unpleasant side-effects. We aimed to investigate the benefit of switch maintenance endocrine therapy plus bevacizumab after fixed cycles of first-line induction chemotherapy with weekly paclitaxel plus bevacizumab in patients with oestrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI